Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, baricitinib treatment led to significant regrowth of scalp, eyebrow, and eyelash hair in alopecia areata patients compared to placebo, with higher effectiveness seen at the 4-mg dose.

In this study on adolescents with severe alopecia areata, baricitinib treatment showed effective scalp, eyebrow, and eyelash regrowth after 52 weeks, benefiting both responders and partial or non-responders, potentially reducing the psychosocial impact of the disease.

This study found that baricitinib was effective in regrowing eyebrow and eyelash hair in patients with severe alopecia areata, with similar improvements observed in both clinician-reported and patient-reported measures.

In this study, baricitinib was evaluated for its effectiveness in promoting concurrent regrowth of scalp hair, eyebrows, and eyelashes in patients with severe alopecia areata, showing clinically meaningful responses compared to placebo.

In this retrospective study, baricitinib and ritlecitinib showed similar effectiveness and safety over 52 weeks for treating severe alopecia areata, with non-severe adverse events more common for baricitinib, driven by weight gain.

This study found that ritlecitinib, taken daily, led to scalp, eyebrow, and eyelash hair regrowth in patients aged 12 and older with severe and very severe alopecia areata over a 24-month period.

This study observed that baricitinib treatment led to significant improvements in hair regrowth and quality of life scores in adults with severe alopecia areata over 24 weeks, with an acceptable safety profile as most adverse effects were transient.

This study found that after 24 weeks of bimatoprost 0.01% treatment, significant improvements in the density and diameter of eyebrow hair were observed, most notably in the tail section of the eyebrow.

In this study, patients with severe alopecia areata treated with baricitinib over 152 weeks experienced sustained patient-reported improvements in scalp, eyebrow, and eyelash hair regrowth, with higher responders observed in the 4mg dose group compared to the 2mg group.

In this study, patients with severe alopecia areata treated with baricitinib showed continued improvement in scalp hair regrowth from weeks 52 to 152, particularly among those initially responding with eyelash or eyebrow regrowth but not scalp hair, with 39% achieving substantial regrowth by week 104.

This study evaluated eyebrow mesotherapy with a growth factor-based cocktail in 32 women with thin eyebrows, finding high satisfaction rates (90.6%) with significant improvements in density and appearance, low pain levels, and unanimous willingness to recommend the treatment.

In this study, LED therapy for eyebrow loss in older females with frontal fibrosing alopecia significantly increased eyebrow hair count after 10 treatments and maintained improvement at 6 months, indicating it could be a promising and well-tolerated treatment option.

This study reported that most patients with alopecia areata who responded to ritlecitinib treatment by achieving a SALT score ≤20, SALT score ≤10, or improvements in eyebrow and eyelash assessments at Week 24 maintained their responses through Week 48.

In this case study, a 34-year-old woman with a rare presentation of pilomatrixoma involving alopecia and skin hypopigmentation showed no improvement in these symptoms despite a 3-month trial of topical steroid treatment, highlighting a potential association between pilomatrixoma and microinflammation.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This study found that among placebo-treated patients in the BRAVE-AA trials, the likelihood of spontaneous hair regrowth in untreated severe alopecia areata was low, with only a small percentage achieving significant scalp, eyebrow, or eyelash hair improvement over 36 weeks.

This study assessed ritlecitinib's effects on sustained hair regrowth in patients with alopecia areata who showed improvement at 24 weeks, confirming ongoing benefits through 48 weeks for scalp, eyebrow, and eyelash hair regrowth in this post hoc analysis.

Using three-hair grafts from the back of the head for eyebrow transplantation offers a natural look and reduces scarring.

This study found that fractional CO(2) laser treatments led to significant improvements in eyelid skin tightening and eyebrow elevation over one year, with no significant side effects reported.

In this case report, tofacitinib led to significant improvement in arthritis and partial improvement in alopecia for a female patient with systemic lupus erythematosus, with no observed adverse effects.

The first Japanese family with Marie Unna hereditary hypotrichosis showed hair condition improvement in a child and highlighted the risk of misdiagnosis.

This study reported that direct brow lift surgery provided excellent and long-lasting results in bald men with high anterior hairlines, despite visibility of the scar in a few cases.

This case report describes a patient with post-combustion alopecia and severe psychiatric issues who experienced significant quality of life improvements and social reintegration following follicular unit extraction.

In this study, daily application of bimatoprost 0.03% ophthalmic solution for 9 months significantly improved eyebrow appearance in individuals with mild to moderate eyebrow hypotrichosis, without observed side effects.

In this multicenter retrospective study, 61.5% of Italian patients with severe alopecia areata achieved significant hair improvement after 52 weeks of treatment with baricitinib, with no major safety issues reported, indicating long-term effectiveness in a real-world setting.

This study found that applying 2% Minoxidil lotion twice daily for four months improved hair diameter and density in individuals with eyebrow hypotrichosis, suggesting it is an effective and well-tolerated treatment; mild side effects like itching and burning were observed in 22.72% of participants.

In this study, baricitinib treatment for severe alopecia areata showed similar safety and led to hair regrowth improvements independent of atopic background, with 40.8% of patients with atopy achieving a significant response compared to 30.2% without atopy when using a 4 mg dose.

This review highlights essential preoperative assessments for ophthalmologists and non-oculo-facial surgeons performing upper facial rejuvenation, emphasizing the importance of understanding ocular and periocular anatomy to achieve both cosmetic and functional improvements.

In this study, the use of Endolift laser treatment significantly improved upper eyelid laxity and eyebrow height in nine patients, with evaluations conducted by blinded physicians showing notable cosmetic outcomes 6 months post-treatment.

In this Italian retrospective study, ritlecitinib 50 mg/day showed effectiveness and good tolerability for treating severe alopecia areata over 24 weeks, achieving significant hair regrowth particularly in adolescents, as well as improvements in eyebrows, eyelashes, nails, and quality of life, with mostly mild adverse effects.